[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sophia Genetics Sa (SOPH)

Sophia Genetics Sa (SOPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 391,973
  • Shares Outstanding, K 71,790
  • Annual Sales, $ 77,270 K
  • Annual Income, $ -79,000 K
  • EBIT $ -72 M
  • EBITDA $ -63 M
  • 60-Month Beta 0.98
  • Price/Sales 4.87
  • Price/Cash Flow N/A
  • Price/Book 8.23

Options Overview Details

View History
  • Implied Volatility 121.76% (+26.63%)
  • Historical Volatility 58.25%
  • IV Percentile 38%
  • IV Rank 16.81%
  • IV High 442.01% on 10/22/25
  • IV Low 57.03% on 09/04/25
  • Expected Move (DTE 27) 0.21 (3.89%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 68
  • Volume Avg (30-Day) 524
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 9,949
  • Open Int (30-Day) 6,200
  • Expected Range 5.25 to 5.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) +356,885.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.51 +21.06%
on 05/19/26
5.51 -0.82%
on 06/08/26
+0.77 (+16.42%)
since 05/18/26
3-Month
4.44 +22.92%
on 05/18/26
5.67 -3.70%
on 05/08/26
+0.55 (+11.20%)
since 03/18/26
52-Week
2.59 +110.81%
on 06/20/25
5.70 -4.21%
on 01/22/26
+2.42 (+79.61%)
since 06/18/25

Most Recent Stories

More News
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares

BOSTON and ROLLE, Switzerland , June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced...

SOPH : 5.46 (+4.20%)
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares

BOSTON and ROLLE, Switzerland , June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced...

SOPH : 5.46 (+4.20%)
SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares

BOSTON and ROLLE, Switzerland , June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten...

SOPH : 5.46 (+4.20%)
SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting

Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board

SOPH : 5.46 (+4.20%)
SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center

SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision Oncology

SOPH : 5.46 (+4.20%)
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.

LONDON , May 13, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers,...

SOPH : 5.46 (+4.20%)
SOPHiA GENETICS Reports First Quarter 2026 Results

BOSTON and ROLLE, Switzerland , May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter...

SOPH : 5.46 (+4.20%)
SOPHiA GENETICS: Whether Platform Economics or Customer Concentration Wins the Narrative

Barchart Research What to Expect from SOPH Earnings SOPH Generated May 4, 2026 Current Price $5.30 Consensus Rating Strong Buy Average Move 5.33% SOPHiA GENETICS: Whether Platform Economics or Customer...

SOPH : 5.46 (+4.20%)
SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026

BOSTON and ROLLE, Switzerland , April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results...

SOPH : 5.46 (+4.20%)
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026

SAN DIEGO and NEW YORK , April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of...

SOPH : 5.46 (+4.20%)

Business Summary

SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights...

See More

Key Turning Points

3rd Resistance Point 5.88
2nd Resistance Point 5.69
1st Resistance Point 5.57
Last Price 5.46
1st Support Level 5.26
2nd Support Level 5.07
3rd Support Level 4.95

See More

52-Week High 5.70
Last Price 5.46
Fibonacci 61.8% 4.51
Fibonacci 50% 4.14
Fibonacci 38.2% 3.78
52-Week Low 2.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.